Use of goserelin in the treatment of breast cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 4, 2005, Pages 591-604

  Rody, Achim ^a   Loibl, Sibylle ^a   von Minckwitz, Gunter ^a   Kaufmann, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Adjuvant treatment; Breast cancer; Goserelin; Palliative treatment; Premenopause

Indexed keywords

4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; ALKYLATING AGENT; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; CALCIUM; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FORMESTANE; GONADORELIN DERIVATIVE; GOSERELIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TAMOXIFEN; TRIPTORELIN; VITAMIN D;

ALOPECIA; AMENORRHEA; ANGINA PECTORIS; ANXIETY; ARTHRALGIA; ARTICLE; BIOLOGICAL ACTIVITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE FERTILITY; FOLLOW UP; FRAGILITY FRACTURE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE REACTION; LIBIDO DISORDER; META ANALYSIS; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; OSTEOPENIA; OVARY CYST; OVARY FUNCTION; PALLIATIVE THERAPY; PREMENOPAUSE; QUALITY OF LIFE; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GOSERELIN; HUMANS; MIDDLE AGED; OVARY; PALLIATIVE CARE; PREMENOPAUSE;

EID: 24044523821     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.4.591     Document Type: Article

References (55)

1. Kiesel L. Molecular mechanisms of gonadotrophin releasing hormone-stimulated gonadotrophin secretion. Human Reprod. Suppl. 2, 23-28 (1993).
2. Naor Z, Shacham S, Harris D et al. Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross talk of calcium, protein kinase C (PKC) and arachidonic acid. Cell. Mol. Neurobiol. 15, 527-544 (1996).
3. Kiesel L, Kaufmann M, Haeseler P et al. GnRH-receptors in primary human breast cancer. Geburtshilfe Frauenheilkd. 48, 420-424 (1988).
4. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol. 166, 740-745 (1992).
5. Surrey ES. Steroidal or nonsteroidal addback therapy: extending safety and efficacy of gonadotropin-releasing hormone agonist in the gynecologic patient. Fertil. Steril. 64, 673-685 (1995).
6. Theriault RL, Sellin RV. Estrogen-replacement therapy in younger women with breast cancer. J. Natl Cancer Inst. Monogr 16, 149-152 (1994).
7. Pujol P, Hilsenbeck SG, Chamness GC et al. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 74, 1601-1606 (1994).
8. Kroman N, Jensen MB, Wohlfahrt J et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. Br. Med. J. 320, 474-478 (2000)
9. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialist's Collaborative Group. Lancet 348, 1189-1196 (1996).
10. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351, 1451-1467 (1998).
11. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355, 1869-1874 (2000).
12. Goldhirsch A, Gelber RD, Yothers G et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J. Natl Cancer Inst. Monogr. 30, 44-51 (2001).
13. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J. Clin. Oncol. 14, 1885-1894 (1996).
14. Jonat W, Kaufmann M, Sauerbrei W et al. Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. The Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol. 20, 4628-4635 (2002).
15. Kaufmann M, Jonat W, Blamey R et al. Zoladex Early Breast Cancer Research Association (ZEBRA) Trialist's Group. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur. J. Cancer 39, 1711-1717 (2003).
16. de Haes H, Olschewski M, Kaufmann M et al. Zoladex Early Breast Cancer Research Association Trialists Group. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer. The Zoladex Early Breast Cancer Research Association Trialists Group. J. Clin. Oncol. 21, 4510-4516 (2003).
17. von Minckwitz G, Graf E, Geberth M et al. Goserelin versus CMF ad adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 Trial. Proceedings of the Am. Soc. Clin. Oncol. Abstr. 534 (2004).
18. Jakesz R, Hausmaninger H, Kubista E et al. Austrian Breast and Colorectal Cancer Study Group Trial 5, Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. Austrian Breast and Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 20, 4621-4627 (2002).
19. Houghton J, Baum M, Rutqvist LE et al. The ZIPP Trial of adjuvant zoladex in premenopausal patients with early breast cancer: an update at five years. Proceedings of the Am. Soc. Clin. Oncol. Abstr. 359 (2000).
20. Baum M, Houghton J, Sawyer W et al. Management of premenopausal women with early breast cancer: is there a role for goserelin? Proceedings of the Am. Soc. Clin. Oncol. 103 (2001).
21. Roche H, Kerbrat P, Bonneterre J et al. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (Pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: results of the FASG 06 Trial. Proceedings of the Am. Soc. Clin. Oncol. 279 (2000).
22. Early Breast Cancer Trialist's Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-717 (2005).
23. Davidson NE, O'Neill A, Vukov A et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: an Eastern Co-operative Oncology Group Phase III intergroup trial (E5188,INT-0101). Proceedings of the Am. Soc. Clin. Oncol. Abstr. 15 (2003).
24. Yarnold JR, Bliss JM, Earl H et al. Ovarian ablation (OA) in pre-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T plus chemotherapy (CT)-results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial of 2,144 patients. Proceedings of the Am. Soc. Clin. Oncol. 535 (2004).
25. Soreide JA, Varhaug JE, Fjosne HE et al. Adjuvant endocrine treatment (goserelin vs. tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur. J. Surg. Oncol. 28, 505-510 (2002).
26. De Placido S, De Laurendis M, De Lena M et al. A randomised factorial trial of sequential doxorubicin and CMF vs. CMF and chemotherapy alone vs. chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br. J. Cancer 92, 467-474 (2005).
27. Castiglione-Gertsch M, O'Neill A, Price KN et al. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J. Natl Cancer Inst. 95, 1833-1846 (2003).
28. Kaufmann M, Graf E, Jonat W et al. Goserelin versus control after adjuvant, risk-adapted chemotherapy inpremenopausal patients with breast cancer. GABG trail IV-B-93. Proceedings of the Am. Soc. Clin. Oncol. 588 (2004).
29. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474-1481 (1999).
30. Nystedt M, Berglund G, Bolund C, Brandberg Y, Fornander T, Rutqvist LE. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer-self-rated physiological effects and symptoms. Acta Oncol. 39, 959-968 (2000).
31. Sagsveen M, Farmer JE, Prentice A et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst. Rev. 4, CD001297 (2003)
32. Sverrisdottir A, Fornander T, Jacobsson H et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J. Clin. Oncol. 22, 3694-3699 (2004).
33. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14, 78-84 (1996).
34. Fogelman I, Blake GM, Blamey R et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int. 14, 1001-1006 (2003).
35. Harris AL, Dowsett M, Jeffcoate SL et al. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocrinol. Metab. 55, 718-722 (1982).
36. Stein RC, Dowsett M, Hedley A et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer 62, 679-683 (1990).
37. Shetty G, Krishnamurthy H, Krishnamurthy HN et al. Effect of estrogen deprivation on the reproductive physiology of male and female primates. J. Steroid. Biochem. Mol. Biol. 61, 157-166 (1997).
38. Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J. Steroid. Biochem. Mol. Biol. 86, 255-263 (2003).
39. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J. Clin. Oncol. 9, 1283-1297 (1991).
40. Cohen I, Figer A, Tepper R et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gyn. Oncol. 72, 202-207 (1999).
41. Kaufmann M, Jonat W, Kleeberg U et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J. Clin. Oncol. 7, 1113-1119 (1989).
42. Blamey RW, Jonat W, Kaufmann M et al. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur. J. Cancer 28A, 810-814 (1992).
43. Taylor CW, Green S, Dalton WS et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J. Clin. Oncol. 16, 994-999 (1998).
44. Boccardo F, Rubagotti A, Perrotta A et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann. Oncol. 5, 337-342 (1994).
45. Jonat W, Kaufmann M, Blamey RW et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur. J. Cancer 31A, 137-142 (1995).
46. Klijn JG, Beex IV, Mauriac L et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cacner: a randomized study. J. Natl Cancer Inst. 92, 903-911 (2000).
47. Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J. Clin. Oncol. 19, 343-53 (2001).
48. Dowsett M, Doody D, Miall S et al. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res. Treat. 56, 25-34 (1999).
49. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br. J. Cancer 90, 590-594 (2004).
50. Carlson RW, Schurman CM, Rivera E et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. 27th Annual San Antonio Breast Cancer Symposium Abstract 6052 (2004).
51. Blumenfeld Z, Avivi I, Linn S et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum. Reprod. 11, 1620-1626 (1996).
52. Blumenfeld Z, Shapiro D, Shteinberg M et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 9, 401-405 (2000).
53. Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a Phase II pilot study. Anticancer Drugs 13, 417-424 (2002).
54. Del Mastro L, Catzeddu T, Boni L et al. Temporary ovarian suppression with goserelin for prevention of chemotherapy-induced menopause in young early breast cancer patients: results of a Phase II study. Proceedings of the Am. Soc. Clin. Oncol. Abstr. 662 (2005).
55. Waxman JH, Ahmed R, Smith D et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother. Pharmacol. 19, 159-162 (1987).